i
Join the status waitlist
No charge, no checkout. Tell us which peptides you're watching and where to reach you.
Longevity, built around you.Licensed US clinicians·Third-party tested
Recovery Peptides · FDA review concluded July 23–24, 2026
BPC-157 and TB-500, the two everyone's pairing. Sorted by what's real.
We won't pretend they're for sale. Here's the honest status of the two recovery peptides everyone asks about: what each does, how they're paired, and a notify-me for the moment either is legitimately available.
★ Get the status the moment FDA rulemaking moves
Free · 30 seconds · no card, no commitment · plain-English FDA updates · unsubscribe anytime
Third-party batch-tested (sterility + endotoxin)Prescription requiredNamed US-licensed clinicianCompounded by a licensed US pharmacy
Live status
Where the two headline peptides actually stand.
The same two-signal status you'll find on our live FDA Tracker. On July 23, 2026 the advisory panel recommended both for the 503A list, a recommendation, not approval or availability, so both are still 🟡 waitlist today.
Next FDA action FDA PCAC · July 23–24, 2026See the live FDA Tracker
Plain English: being recommended by an advisory panel is not the same as being legal to compound, and neither is the same as being available to buy. On July 23, 2026 both were recommended for the 503A list, FDA rulemaking must still follow. We track each and update it as the agency acts, and we will not sell what we can't stand behind.
Seen enough? Get the status the moment it changes.
★ Get the status the moment FDA rulemaking moves. Free, no card.
BPC-157 vs TB-500
BPC-157 vs TB-500, told straight.
They're different peptides, almost always discussed together: the pairing the internet nicknamed the “Wolverine stack.” Here's what each is for, the honest evidence on both, and why pairing them doesn't double the proof.
Both were recommended by the FDA's advisory committee on July 23, 2026 for the 503A compounding list — a recommendation, not approval or availability. Both remain waitlist/education-only here. The vote does not upgrade the evidence: both are still grade D.
BPC-157The flagship
What it does
A 15-amino-acid peptide derived from a protein found in gastric juice. Taken in hope of supporting tendon, joint, muscle, and gut-lining recovery: the most-discussed of the recovery peptides.
Best evidence
Animal-dominant data with high interest. The marketing is far louder than the human evidence, which is thin.
What we don't know
Evidence grade D: fewer than 30 humans studied, no placebo-controlled efficacy trials. WADA-banned (S0).
TB-500The pairing
What it does
A synthetic 7-amino-acid fragment related to thymosin beta-4 (Tβ4). Discussed for soft-tissue and tendon recovery, almost always alongside BPC-157.
Best evidence
Even earlier than BPC-157 on human data, and the marketed fragment differs from trial-grade thymosin beta-4.
What we don't know
Evidence grade D, plus an immunogenicity question: antibody responses have been raised for the fragment. WADA-banned (S0). The marketed fragment isn't trial-grade Tβ4.
Why they're paired
The theory is complementary: BPC-157 for the gut-and-soft-tissue angle, TB-500 for soft-tissue repair, and both sit under the same FDA review. If and when both become legitimately available, we'd expect to offer them as a paired recovery approach. But be clear-eyed: pairing two grade-D peptides doesn't double the evidence.
The pairing people call the “Wolverine stack”, sorted honestly. Go deeper in the Knowledge Base, or check both peptides live on the FDA Tracker.
Find your path
The recovery line, sorted by what you're here for.
Each routes to its honest status page and a waitlist, never a checkout. Browse to the one that fits.
The Wolverine stack
BPC-157 as the local repair signal, TB-500 as the systemic one, the pair people call “Wolverine.” See the honest status of both and claim your spot at the front of the line.
The flagship
You've seen BPC-157 everywhere and want the real regulatory status, not the hype.
The recovery pairing
You already know BPC-157 and want the peptide it's usually paired with for soft-tissue recovery.
Joint, tendon & injury
You've got a nagging injury that won't settle and want the honest recovery-peptide landscape.
Gut repair
Gut issues nobody's solved, and you want the BPC-157 and KPV conversation, told straight.
Why we do it this way
Transparency is the whole strategy.
Everyone else is racing to sell these the moment a headline drops. We're doing the opposite, and it's not charity. Being the operator who tells you exactly where it stands is how we earn the relationship.
What we do
Sort by what's real
We publish the actual regulatory status of each peptide: the two-signal pill and the plain-English verdict, updated as the FDA acts.
What we won't do
Sell you the hype
If it's under review and not legitimately available, we say so. No prices, no “buy now,” no availability promises we can't keep.
What you get
First in line
Join the waitlist and you hear first: the moment it's legitimately available through a licensed pharmacy, before any public launch.
Recovery is episodic: you come in for one injury and heal. So the honest move is also the smart one: we set you up in a longevity protocol that's actually available now, so you're cared for between catalysts instead of churning.
Seven peptides are under FDA review, none has been reclassified. The July 23–24 meeting is advisory; a favorable vote starts a process that takes well into 2027. We'll tell you exactly where each one stands, and notify you the moment anything legitimately changes.
The peptide therapeutics market is projected to grow from roughly $141B (2025) to $295B by 2033. (Grand View Research, 2026)
Why sourcing is the whole game
The molecule is easy to find. The safe version isn’t.
Most peptides online ship under a “research use only: not for human consumption” label. That one phrase lets a seller skip FDA oversight, sterility testing, and any real manufacturing standard, and hands the entire risk to you.
What you’re not getting here
- No research-chemical vials.
- No “not for human use” labels.
- No anonymous overseas seller.
- A clinician, a licensed pharmacy, and a test result you can actually see.
The Peptós.LIFE lane
Prescribed by a US-licensed clinician. Compounded in a US-licensed 503A/503B pharmacy to USP sterility and potency standards. Third-party tested every batch: identity, potency, and sterility. Monitored as an actual clinical relationship, not a one-time sale.
Compounded medications are not FDA-approved. Where that applies, we say so. Status and timelines are tracked openly on our FDA Tracker.
See exactly where every compound standsPowered by a clinical network that supports 3M+ patients a year and 20,000+ licensed clinicians across all 50 states.
How it works
How the waitlist works.
ii
We track the FDA review for you
We publish the real status on the live Tracker and email plain-English updates as the PCAC review proceeds.
iii
You hear first, if it's legitimately available
Only if and when the review concludes favorably and fulfillment through a licensed pharmacy is confirmed. Waitlist members are notified before any public launch.
Questions, answered
The honest answers, the ones the hype skips.
Not to prescribe today. On July 23, 2026 the FDA's advisory committee (PCAC) voted to recommend it for the 503A compounding list, but a recommendation is not approval or availability, FDA rulemaking must follow, realistically late 2026 into 2027. We track the real status on the live FDA Peptide Tracker and update it as the agency acts.
Not from us. The headline recovery peptides are not yet available to prescribe, and we won't sell something we can't stand behind. Join the waitlist and you'll be first to know the moment any of them is legitimately available.
The FDA's Pharmacy Compounding Advisory Committee reviewed peptides including BPC-157 and TB-500 on July 23–24, 2026. On July 23 it voted to recommend BPC-157, KPV, TB-500 and MOTS-c for the 503A list, against FDA staff advice. That recommendation is advisory: FDA rulemaking must follow before anything can be compounded for patients, realistically late 2026 into 2027. We've published the outcome on the Tracker.
They're different peptides usually discussed together for recovery, and they're under the same review. BPC-157 is the gut-and-soft-tissue flagship; TB-500 is the soft-tissue pairing, and it carries an extra immunogenicity question, with the marketed fragment differing from trial-grade thymosin beta-4. Both are grade-D and waitlist-only today. See the side-by-side comparison above for the honest detail. Pairing them doesn't double the evidence.
It's the internet nickname for pairing BPC-157 with TB-500 for recovery, the two peptides everyone discusses together. Both are evidence grade D and both sit under the same FDA compounding review, so neither is for sale from us today. We sort the pairing honestly in the comparison above, explain each in the Knowledge Base, and track both on the live FDA Peptide Tracker. Pairing two grade-D peptides doesn't double the evidence.
Yes. See the available-now band near the top of this page: Sermorelin, the GH-axis recovery support, is clinician-prescribed and available today inside our Longevity protocols (the restricted CJC-1295/Ipamorelin are education-only).
Only if and when the review concludes favorably and fulfillment through a licensed pharmacy is confirmed. No promises on timing, but waitlist members hear first, before any public launch.
No. Compounded medications are not FDA-approved; they're prepared by licensed pharmacies for an individual patient when a clinician determines they're appropriate. Today, these recovery peptides aren't even at that stage; they're under review.
Go deeper
Read the evidence yourself.
Hubs link across to the Knowledge Base, out to the live FDA status, and into the longevity protocol that's available today.
Live FDA Peptide TrackerThe real regulatory status of every peptide, updated as the agency acts.Recovery & Gut: JTBD hubsThe molecules behind recovery and gut repair, graded plainly.BPC-157, TB-500, GHK-Cu, KPV monographsMechanism, evidence grade, and the honest unknowns.Longevity: available todayEpisodic recovery? Sermorelin and the longevity stack are here now.
Get notified
Be first in line, the honest way.
Join the status waitlist. We'll notify you the moment these recovery peptides are legitimately available, and keep you posted on the FDA review in plain English. After the July review we'll email you the outcome in plain English, favorable or not, plus your spot if anything becomes available.
No charge. No spam. Just the status, and your spot at the front of the line. By joining you agree to receive email and SMS updates; opt out anytime.